6.2 Serology of Infectious Diseases

Serology of Infectious Diseases

Serological testing is a cornerstone of the clinical microbiology and immunology laboratory. It is particularly invaluable for diagnosing infections caused by organisms that are fastidious (exceedingly difficult or slow to grow in culture), hazardous to handle, or when the patient presents late in the disease course after the pathogen has been cleared but tissue damage remains. Serology primarily involves detecting the host's antibody response to an infection (indirect diagnosis) or directly detecting pathogen antigens circulating in the serum.

Viral Serology Panels: The Hepatitis Viruses

Viral hepatitis is a systemic disease primarily affecting the liver. While several distinct viruses exist (A, B, C, D, E), they present with remarkably similar clinical symptoms (jaundice, fatigue, elevated liver transaminases ALT/AST). Accurate serological testing is strictly required to determine the specific viral etiology and stage the infection.

Hepatitis A and C

• Hepatitis A Virus (HAV): Transmitted via the fecal-oral route, causing an acute, self-limiting disease. It does not progress to chronic hepatitis. Diagnosis is established by testing for Anti-HAV IgM, which indicates an acute infection. Anti-HAV IgG indicates a past infection and confers lifelong immunity. Total Anti-HAV measures both.
• Hepatitis C Virus (HCV): Primarily bloodborne. A high percentage of acute cases silently progress to chronic hepatitis, leading to severe cirrhosis and hepatocellular carcinoma decades later. Screening relies on detecting Anti-HCV (antibodies to the virus). Because antibodies can persist even if the patient naturally clears the virus, any positive Anti-HCV screen must be reflexed to a confirmatory HCV RNA test by quantitative RT-PCR to detect active viral replication. Genotyping the virus is also critical for guiding modern direct-acting antiviral (DAA) therapy.

Hepatitis B Serological Markers

Hepatitis B virus (HBV) is a hepatotropic DNA virus. Infection can result in acute hepatitis, or it can progress to a chronic carrier state. Diagnosis relies on a careful analysis of multiple serological markers, as their appearance and clearance follow a highly predictable timeline.

• HBsAg (Hepatitis B surface antigen): This is the protein envelope of the virus. It is the first serological marker to appear in an acute infection, often detectable weeks before the onset of clinical symptoms or elevated liver enzymes. Its presence definitively indicates active viral replication and patient infectivity. If HBsAg persists in the serum for greater than 6 months, the patient has progressed to chronic Hepatitis B.
• HBeAg (Hepatitis B e antigen): A soluble protein derived from the viral core. It appears shortly after HBsAg. Positivity for HBeAg correlates with extremely high levels of viral DNA; thus, it indicates highly active viral replication and a high degree of infectivity.
• Anti-HBc Total (IgM and IgG antibodies to core antigen): The core antigen (HBcAg) itself is localized within the nuclei of infected hepatocytes and does not freely circulate in the blood, so it is not routinely measured. However, the host produces massive amounts of antibodies against it. Anti-HBc IgM is the first antibody to appear and signifies an acute or very recent infection. Eventually, the IgM wanes, and Anti-HBc IgG predominates. A positive "Total Core Antibody" test indicates that the patient has had a natural HBV infection at some point in their life, regardless of whether it cleared or became chronic.
• The "Core Window": There is a distinct, critical phase in an acute, resolving HBV infection where the virus is being rapidly cleared, causing HBsAg to disappear, but the neutralizing surface antibodies (Anti-HBs) have not yet reached detectable thresholds. During this serological "gap" or "core window," the only positive marker is Anti-HBc IgM. Testing for this marker prevents false-negative diagnoses during this period.
• Anti-HBe (Antibody to e antigen): Seroconversion from HBeAg to Anti-HBe indicates a significant decrease in viral replication, dramatically reducing the patient's infectivity and generally signaling a favorable prognosis for disease resolution.
• Anti-HBs (Hepatitis B surface antibody): This is the neutralizing, protective antibody. Its appearance signifies clinical recovery and lifelong immunity following natural infection. It is identically the specific antibody produced in response to the Hepatitis B vaccine (which consists purely of recombinant HBsAg).

Interpreting Hepatitis B Panels

Understanding combinations of these markers is frequently tested on certification exams.

HIV Testing Algorithms

The diagnostic algorithm for Human Immunodeficiency Virus (HIV) has undergone significant revision over the years to drastically improve early detection, limit transmission, and precisely differentiate between HIV-1 and HIV-2. Earlier testing paradigms relied on an ELISA screening test confirmed by a laborious Western Blot. This older approach suffered from a prolonged "window period" (the time between initial infection and serological detectability), potentially missing highly infectious acute cases.

Current Standard: 4th Generation Testing

The CDC currently strongly recommends an initial screening with a 4th generation HIV-1/2 antigen/antibody combination immunoassay.

These highly advanced assays simultaneously detect:

1. HIV-1 and HIV-2 IgG and IgM antibodies: To capture the host's robust humoral response.
2. HIV-1 p24 antigen: A major structural core capsid protein of the virus. Levels of p24 rise significantly and spike in the blood during the acute phase of infection, well before the host is capable of mounting a detectable antibody response.

Clinical Significance: By directly detecting the p24 viral antigen, 4th generation tests dramatically narrow the window period, allowing definitive detection of HIV as early as 14 to 20 days post-exposure. This early detection is critical for initiating early antiretroviral therapy (ART) and preventing onward transmission.

Confirmatory Algorithm

Because of the severe medical and psychosocial implications of an HIV diagnosis, any repeatedly reactive screening test must be unequivocally confirmed through a multi-step algorithm.

1. If the 4th generation combination test is positive, the sample is automatically reflexed to an HIV-1/HIV-2 antibody differentiation assay (such as the Geenius or Multispot test). This rapid test definitively distinguishes whether the antibodies are targeting HIV-1 or HIV-2 (which has major implications for clinical monitoring and drug selection).
2. If the differentiation assay is reactive for either, the diagnosis is confirmed.
3. If the differentiation assay is non-reactive or indeterminate, a critical discrepancy exists. It highly suggests the patient may be in the earliest acute phase where only the p24 antigen is present (triggering the 4th gen test), but specific antibodies have not fully developed (failing the differentiation test). In this precise scenario, the algorithm strictly requires a reflex to an HIV-1 Nucleic Acid Test (NAT) to detect viral RNA and definitively confirm an acute viral infection.

Once diagnosed, patients are monitored using Viral Load testing (Quantitative RT-PCR) to assess ART efficacy, and CD4 T-cell counts (Flow Cytometry) to monitor absolute immune system competence and risk of opportunistic infections.

Syphilis Testing

Syphilis is a notoriously complex sexually transmitted infection caused by the delicate spirochete Treponema pallidum. The disease progresses through distinct clinical stages: primary (painless, localized chancre), secondary (highly infectious disseminated rash, lymphadenopathy), latent (asymptomatic), and tertiary (destructive gummatous lesions, cardiovascular, or neurosyphilis). Because T. pallidum cannot be cultured in vitro on any artificial media, serology is the absolute mainstay of laboratory diagnosis.

Testing is divided into two broad categories: non-treponemal and treponemal tests.

Non-Treponemal Tests (Screening and Monitoring)

These tests do not detect antibodies against the bacterium itself. Instead, they detect "reagin" antibodies, which are non-specific IgA, IgM, and IgG antibodies produced in response to lipoidal material (cardiolipin, cholesterol, lecithin) released from host cells damaged by the spirochete, as well as lipids from the treponeme itself. They are cheap, rapid, and highly sensitive screening tools.

• VDRL (Venereal Disease Research Laboratory): A microscopic flocculation test. The antigen is a highly controlled lipid mixture prepared fresh daily on a glass slide. The VDRL is critically important as it remains the only serological test validated and approved for testing Cerebrospinal Fluid (CSF) to diagnose neurosyphilis.
• RPR (Rapid Plasma Reagin): A macroscopic flocculation test universally used for testing serum. It modifies the VDRL antigen by incorporating finely milled charcoal particles, allowing the resulting flocculation (black clumps against a white plastic card) to be read easily with the naked eye.

Key Characteristics of Non-Treponemal Tests:

• Titers: They are strictly quantitative. Serial dilutions (1:2, 1:4, 1:8, 1:16, etc.) are performed to determine the highest titer showing reactivity. Titers correlate directly with disease activity. A fourfold decrease in titer (e.g., 1:32 dropping to 1:8) definitively indicates successful antibiotic treatment. Therefore, they are the required assays to monitor treatment efficacy.
• False Positives: Because they detect common anti-lipid antibodies, biological false positives (BFPs) can and do occur due to pregnancy, systemic autoimmune diseases (like SLE), advanced age, or transiently during other infections (hepatitis, infectious mononucleosis). All positive screening tests must be confirmed.
• Prozone: Due to the extremely high antibody titers generated during secondary syphilis, a massive prozone effect can occur, leading to a deceivingly weak or even completely false-negative result in an undeniably symptomatic patient unless the serum is appropriately diluted by the laboratory.

Treponemal Tests (Confirmatory)

These tests detect specific antibodies directed against highly specific T. pallidum cellular antigens. They are used to confirm reactive non-treponemal screening tests.

• FTA-ABS (Fluorescent Treponemal Antibody Absorption): The traditional, historical "gold standard." It is a complex indirect immunofluorescence assay. A crucial and defining step involves actively absorbing the patient's serum with a purified extract of non-pathogenic Reiter treponemes to effectively remove any cross-reacting antibodies, thereby vastly enhancing specificity before applying the serum to the pathogenic T. pallidum slide.
• TP-PA (Treponema pallidum Particle Agglutination): Employs colored gelatin particles sensitized with T. pallidum antigens. Patient serum is added, and positive results show a smooth, diffuse mat of agglutinated particles across a microtiter well, while negative results settle into a tight, distinct button at the bottom.

Key Characteristics of Treponemal Tests:

• Once a patient develops treponemal antibodies, they typically remain seropositive for life, even after fully successful antibiotic treatment. Therefore, treponemal tests cannot be used to distinguish between a currently active disease and a past, treated infection, nor can they be used to monitor therapeutic response over time.

The Reverse Sequence Algorithm

Traditionally, the algorithm was: Screen with RPR -> Confirm with TP-PA. Due to the massive high volume of screening required in modern automated reference laboratories, the CDC now officially endorses a "Reverse Algorithm."

1. Screen broadly with an automated, high-throughput Treponemal Immunoassay (EIA or CIA).
2. If the EIA is reactive, automatically reflex to a quantitative Non-treponemal test (RPR) to precisely determine if the disease is currently active and to establish a critical baseline titer for treatment monitoring.
3. If the initial EIA is reactive but the subsequent RPR is non-reactive (suggesting a past treated infection, very early primary syphilis, or a false-positive EIA), a second, completely different treponemal methodology (like TP-PA) is performed as an ultimate tie-breaker to rule out a false-positive EIA screen.

Epstein-Barr Virus (EBV) Serology

EBV is the causative agent of infectious mononucleosis. Initial screening utilizes a rapid test for heterophile antibodies (the Monospot test). Heterophile antibodies are non-specific antibodies that remarkably cross-react with antigens on sheep or horse red blood cells, causing them to agglutinate. While rapid and useful, heterophile tests can be falsely negative in young children (under 4) and some adults.

When heterophile tests are negative but symptoms persist, or for complex cases, an EBV Specific Serology Panel is ordered:

• VCA IgM (Viral Capsid Antigen IgM): Appears early in acute infection and disappears within months.
• VCA IgG: Appears in acute phase, peaks at 2-4 weeks, and persists for life, indicating past exposure.
• EA-D (Early Antigen, Diffuse): Appears in the acute phase and generally disappears upon recovery.
• EBNA (EBV Nuclear Antigen): Crucially, antibodies to EBNA do not appear until the convalescent phase (months later) and persist for life. A positive EBNA categorically rules out a current, acute primary infection and signifies established, historical immunity.